Emerging Roles of NcRNAs in Type 2 Diabetes Mellitus: From Mechanisms to Drug Discovery

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Nov 27

PMID 39595541

Authors

Yue Yang

Hao Cheng

Affiliations

Soon will be listed here.

Abstract

Type 2 diabetes mellitus (T2DM), a high-incidence chronic metabolic disorder, has emerged as a global health issue, where most patients need lifelong medication. Gaining insights into molecular mechanisms involved in T2DM development is expected to provide novel strategies for clinical prevention and treatment. Growing evidence validates that non-coding RNAs (ncRNAs) including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) function as crucial regulators in multiple biological processes of T2DM, inspiring various potential targets and drug candidates. In this review, we summarize the current understanding of ncRNA roles in T2DM and discuss the potential use of ncRNAs as targets and active molecules for drug discovery.

Citing Articles

Li L, Wu Y, Yang J Int J Mol Sci. 2025; 26(5).

PMID: 40076814 PMC: 11900361. DOI: 10.3390/ijms26052194.

References

Jia N, Wu H, Duan J, Wei C, Wang K, Zhang Y . Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo. J Vis Exp. 2019; (144). DOI: 10.3791/58660. View

Kara G, Calin G, Ozpolat B . RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022; 182:114113. DOI: 10.1016/j.addr.2022.114113. View

Khansarizadeh M, Mokhtarzadeh A, Rashedinia M, Taghdisi S, Lari P, Abnous K . Identification of possible cytotoxicity mechanism of polyethylenimine by proteomics analysis. Hum Exp Toxicol. 2015; 35(4):377-87. DOI: 10.1177/0960327115591371. View

Murphy D, de Jong O, Evers M, Nurazizah M, Schiffelers R, Vader P . Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles. Nano Lett. 2021; 21(4):1888-1895. PMC: 8023702. DOI: 10.1021/acs.nanolett.1c00094. View

Ferre F, Colantoni A, Helmer-Citterich M . Revealing protein-lncRNA interaction. Brief Bioinform. 2015; 17(1):106-16. PMC: 4719072. DOI: 10.1093/bib/bbv031. View

Zhang F, Ma D, Zhao W, Wang D, Liu T, Liu Y . Obesity-induced overexpression of miR-802 impairs insulin transcription and secretion. Nat Commun. 2020; 11(1):1822. PMC: 7156651. DOI: 10.1038/s41467-020-15529-w. View

Chen L, Yang L . Regulation of circRNA biogenesis. RNA Biol. 2015; 12(4):381-8. PMC: 4615371. DOI: 10.1080/15476286.2015.1020271. View

Chen L, Sun X, Xiao H, Xu F, Yang Y, Lin Z . PAQR3 regulates phosphorylation of FoxO1 in insulin-resistant HepG2 cells via NF-κB signaling pathway. Exp Cell Res. 2019; 381(2):301-310. DOI: 10.1016/j.yexcr.2019.04.031. View

Han J, Chen Y, Xu X, Li Q, Xiang X, Shen J . Development of Recombinant High-Density Lipoprotein Platform with Innate Adipose Tissue-Targeting Abilities for Regional Fat Reduction. ACS Nano. 2024; 18(21):13635-13651. DOI: 10.1021/acsnano.4c00403. View

10.

Huang X, Ma Y, Ma G, Xia Y . Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies. Research (Wash D C). 2024; 7:0370. PMC: 11185168. DOI: 10.34133/research.0370. View

11.

Ashwal-Fluss R, Meyer M, Pamudurti N, Ivanov A, Bartok O, Hanan M . circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56(1):55-66. DOI: 10.1016/j.molcel.2014.08.019. View

12.

Springer A, Dowdy S . GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Nucleic Acid Ther. 2018; 28(3):109-118. PMC: 5994659. DOI: 10.1089/nat.2018.0736. View

13.

Letonja J, Petrovic D . A Review of MicroRNAs and lncRNAs in Atherosclerosis as Well as Some Major Inflammatory Conditions Affecting Atherosclerosis. Biomedicines. 2024; 12(6). PMC: 11201627. DOI: 10.3390/biomedicines12061322. View

14.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

15.

Jeong M, Lee Y, Park J, Jung H, Lee H . Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv Drug Deliv Rev. 2023; 200:114990. DOI: 10.1016/j.addr.2023.114990. View

16.

Erener S, Mojibian M, Fox J, Denroche H, Kieffer T . Circulating miR-375 as a biomarker of β-cell death and diabetes in mice. Endocrinology. 2013; 154(2):603-8. DOI: 10.1210/en.2012-1744. View

17.

Lu J, Pang L, Zhang B, Gong Z, Song C . Silencing circANKRD36 inhibits streptozotocin-induced insulin resistance and inflammation in diabetic rats by targeting miR-145 via XBP1. Inflamm Res. 2021; 70(6):695-704. DOI: 10.1007/s00011-021-01467-w. View

18.

Li Y, Zhang T, Zhou Y, Sun Y, Cao Y, Chang X . A Presenilin/Notch1 pathway regulated by miR-375, miR-30a, and miR-34a mediates glucotoxicity induced-pancreatic beta cell apoptosis. Sci Rep. 2016; 6:36136. PMC: 5095347. DOI: 10.1038/srep36136. View

19.

Wan Q, Huang B, Li T, Xiao Y, He Y, Du W . Selective targeting of visceral adiposity by polycation nanomedicine. Nat Nanotechnol. 2022; 17(12):1311-1321. DOI: 10.1038/s41565-022-01249-3. View

20.

Jadhav V, Vaishnaw A, FitzGerald K, Maier M . RNA interference in the era of nucleic acid therapeutics. Nat Biotechnol. 2024; 42(3):394-405. DOI: 10.1038/s41587-023-02105-y. View